Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 19/01/2021
• Auteurs : Stanislas PolDelphine BonnetVirginie Payssan-SicartChloe PomesFrançois BaillyMarjolaine BeaudoinDominique GibozKerstin Hartig-LavieMarianne MaynardEric BillaudDavid BoutoilleMorane CavellecCaroline ChevalierIsabelle HubertPierre GoepfertAdrien LannesFrançois LunelJérôme BoursierNathalie BoyerNathalie GiuilyCorinne CastelnauGiovanna ScoazecAziza ChibahSylvie KeserKarim BonardiAnaïs Vallet-PichardPhilippe SogniJuliette FoucherJean-Baptiste HiriartAmandine LegendreFaiza ChermakMarie Irlès-DepéSi Nafa Si AhmedChristelle AnsaldiNisserine Ben AmaraValérie OulesJacqueline DunetteRodolphe AntyEve GelsiRégin TruchiElena LuckinaNadia MessaoudiJoseph MoussaliBarbara De DieuleveultHéloïse GoinDamien LabarrièrePascal PotierSi Nafa Si AhmedVéronique Grando-LemairePierre NahonSéverin BruléRym MonardCaroline JezequelAudrey BrenerAnne LaligantAline RabotIsabelle RenardThomas F BaumertMichel DofföelCatherine MutterPauline Simo-NoumbissieEsma RaziHélène BarraudMouni BensenaneAbdelbasset NaniSarah Hassani-NaniMarie-Albertine BernardGeorges-Philippe PageauxMichael BismuthLudovic CailloStéphani FaureMarie Pierre RipaultChristophe BureauSarah LaunayJean Marie PeronMarie Angèl RobicLé TaralloMarine FaureBruno FroissartMarie-Noelle HilleretJean-Pierre ZarskiOdile GoriaVictorien GrardHélè E MontialouxMuriel FrançoisChristian OuedraogoChristelle PauleauAnne VaraultTony AndreaniBénédic E AngoulevantAzeline ChevanceLawrence SerfatyTeresa AntoniniAudrey CoillyJean-Charles Duclos ValléeMariagrazia TateoCorinne BonnyChanteranne BrigitteGéraldin LamblinLéo MutiAbdenour BabouriVirginie FilipeCamille BarraultLaurent CostesSoraya MerbahPaul CarrierMaryline Debette-GratienJérémie JacquesGuillaume LassaillyFlorent ArtuValérie CanvaSébastie DharancyAlexandre LouvetMarianne LatournerieMarc BardouThomas MouillotYannick BacqDidier BarbereauCharlotte NicolasCaroline ChevalierIsabelle ArchambeaudSarah HabesNisserine Ben AmaraDanièl Botta-FridlundEric SaillardMarie-José LafranceClovis Luzivika NzingaCéline DorivalFabien ZoulimCarole CagnotThomas DecaensDominique ThabutTarik AsselahPhilippe MathurinNathalie GanneDidier SamuelFrançoi HabersetzerJean-Pierre BronowickiDominique GuyaderIsabelle RosaVincent LeroyOlivier ChazouilleresVictor De LedinghenMarc BourliereXavier CaussePaul CalèsSophie MetivierVéroniqu Loustaud-RattiArmand AbergelHélène FontaineFabrice Carrat
• Organismes : Département d'hépatologie [CHU Cochin] Physiopathologie du système immunitaire Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique
• Publié dans Alimentary Pharmacology & Therapeutics (Suppl) le 26/10/2020

---

Résumé : Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications. Aim: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort. Methods: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW). Results: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively. Conclusion: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients. Trial registration number: NCT019553458.

---

Fichiers liés : Pol et Group - 2021 - Similar 5-year HCC occurrence in Tenofovir- and En.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 14/01/2021
• Auteurs : Guillaume Quang N’guyenRoxane RauloA. PorquierBeatrice IacomiSandra PelletierJean-Pierre RenouNelly Bataillé-SimoneauClaire CampionBruno HamonAnthony KwasiborskiJustine ColouAbdelilah BenamarPiétrick HudhommeDavid MacherelPhilippe SimoneauThomas Guillemette
• Organismes : Institut Charles Viollette (ICV) - ULR 7394 BIOlogie et GEstion des Risques en agriculture University of Agronomical Sciences and Veterinary Medicine of Bucharest Institut de Recherche en Horticulture et Semences Institut de Recherche en Horticulture et Semences Institut de Recherche en Horticulture et Semences IRHS - Équipe FungiSem (Pathologies Fongiques des Semences) Institut de Recherche en Horticulture et Semences IRHS - Équipe FungiSem (Pathologies Fongiques des Semences) Institut de Recherche en Horticulture et Semences IRHS - Équipe FungiSem (Pathologies Fongiques des Semences) Institut de Recherche en Horticulture et Semences Institut de Recherche en Horticulture et Semences Institut de Recherche en Horticulture et Semences MOLTECH-Anjou Institut de Recherche en Horticulture et Semences Institut de Recherche en Horticulture et Semences IRHS - Équipe FungiSem (Pathologies Fongiques des Semences) Institut de Recherche en Horticulture et Semences IRHS - Équipe FungiSem (Pathologies Fongiques des Semences)
• Publié dans Frontiers in Plant Science le 24/10/2020

---

Résumé : Alternaria brassicicola is the causative agent of black spot disease in Brassicaceae. During host infection, this necrotrophic fungus is exposed to high levels of antimicrobial defence compounds, such as the indolic phytoalexin brassinin. To gain insights into the cellular mechanisms by which this compound exerts its toxicity and investigate the adaptive strategies used by the fungus, we first analyzed fungal transcriptional responses to short-term exposure to brassinin and then used additional functional approaches. This study supports the hypothesis that indolic phytoalexin primarily targets mitochondrial functions in fungal cells. Indeed, we notably observed that phytoalexin treatment of A. brassicicola disrupted the mitochondrial membrane potential and resulted in a significant and rapid decrease in the oxygen consumption rates. Secondary effects, such as ROS production, changes in lipid and endoplasmic reticulum (ER) homeostasis were then found to be induced. Consequently, the fungus has to adapt its metabolism to protect itself against the toxic effects of these molecules, especially via the activation of high osmolarity glycerol (HOG) and cell wall integrity (CWI) signaling pathways and by induction of the unfolded protein response (UPR).

---

Fichiers liés : fpls-11-611643.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/01/2021
• Auteurs : Pierre SenersWagih Ben HassenBertrand LapergueCaroline ArquizanMirjam Rachel HeldnerHilde HenonClaire PerrinDavide StramboJean-Philippe CottierDenis SablotIsabelle Girard-ButtazRuben TamazyanCécile PreterrePierre AgiusNadia LaksiriLaura MechtouffYannick BejotDuc-Long DuongFrancois Mounier-VehierGioia MioneCharlotte RossoLudovic LucasJérémie PapassinAndreea AignatoaieAude TriquenotEmmanuel CarreraPhilippe NiclotAlexandre ObadiaAïcha LyoubiPierre GarnierNicolae CrainicValérie WolffClément TracolFrédéric PhilippeauChantal LamySébastien SoizeJean Claude BaronGeorgios Tsivgoulis
• Organismes : Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris Hôpital Foch [Suresnes] Hôpital Gui de Chauliac [CHU Montpellier] Bern University Hospital [Berne] Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 Institut de psychiatrie et neurosciences de Paris Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Hôpital Bretonneau Centre Hospitalier Saint Jean de Perpignan Centre hospitalier [Valenciennes, Nord] Centre hospitalier Saint-Joseph [Paris] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre hospitalier de Saint-Nazaire Hôpital de la Timone [CHU - APHM] Hospices Civils de Lyon Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier de Versailles André Mignot Université de Versailles Saint-Quentin-en-Yvelines Centre Hospitalier de Lens Centre Hospitalier Régional Universitaire de Nancy Institut du Cerveau = Paris Brain Institute Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Métropole Savoie [Chambéry] Centre Hospitalier Regional d'Orléans CHU Rouen Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Centre Hospitalier René Dubos [Pontoise] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Hôpital Delafontaine Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire [Rennes] Centre Hospitalier Fleyriat [Bourg en Bresse] CHU Amiens-Picardie Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Hôpital universitaire Robert Debré [Reims] Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris
• Publié dans JAMA neurology le 24/10/2020

---

Résumé : Importance: The best reperfusion strategy in patients with acute minor stroke and large vessel occlusion (LVO) is unknown. Accurately predicting early neurological deterioration of presumed ischemic origin (ENDi) following intravenous thrombolysis (IVT) in this population may help to select candidates for immediate transfer for additional thrombectomy. Objective: To develop and validate an easily applicable predictive score of ENDi following IVT in patients with minor stroke and LVO. Design, setting, and participants: This multicentric retrospective cohort included 729 consecutive patients with minor stroke (National Institutes of Health Stroke Scale [NIHSS] score of 5 or less) and LVO (basilar artery, internal carotid artery, first [M1] or second [M2] segment of middle cerebral artery) intended for IVT alone in 45 French stroke centers, ie, including those who eventually received rescue thrombectomy because of ENDi. For external validation, another cohort of 347 patients with similar inclusion criteria was collected from 9 additional centers. Data were collected from January 2018 to September 2019. Main outcomes and measures: ENDi, defined as 4 or more points' deterioration on NIHSS score within the first 24 hours without parenchymal hemorrhage on follow-up imaging or another identified cause. Results: Of the 729 patients in the derivation cohort, 335 (46.0%) were male, and the mean (SD) age was 70 (15) years; of the 347 patients in the validation cohort, 190 (54.8%) were male, and the mean (SD) age was 69 (15) years. In the derivation cohort, the median (interquartile range) NIHSS score was 3 (1-4), and the occlusion site was the internal carotid artery in 97 patients (13.3%), M1 in 207 (28.4%), M2 in 395 (54.2%), and basilar artery in 30 (4.1%). ENDi occurred in 88 patients (12.1%; 95% CI, 9.7-14.4) and was strongly associated with poorer 3-month outcomes, even in patients who underwent rescue thrombectomy. In multivariable analysis, a more proximal occlusion site and a longer thrombus were independently associated with ENDi. A 4-point score derived from these variables-1 point for thrombus length and 3 points for occlusion site-showed good discriminative power for ENDi (C statistic = 0.76; 95% CI, 0.70-0.82) and was successfully validated in the validation cohort (ENDi rate, 11.0% [38 of 347]; C statistic = 0.78; 95% CI, 0.70-0.86). In both cohorts, ENDi probability was approximately 3%, 7%, 20%, and 35% for scores of 0, 1, 2 and 3 to 4, respectively. Conclusions and relevance: The substantial ENDi rates observed in these cohorts highlights the current debate regarding whether to directly transfer patients with IVT-treated minor stroke and LVO for additional thrombectomy. Based on the strong associations observed, an easily applicable score for ENDi risk prediction that may assist decision-making was derived and externally validated.

---

Fichiers liés : Seners et al_JAMA neurol 2021.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/01/2021
• Auteurs : Izanne RoosEmmanuelle LerayFederico FrascoliRomain CaseyJ William L BrownDana HorakovaEva HavrdovaMarc DebouverieMaria TrojanoFrancesco PattiGuillermo Izquierdo AyusoSara Eichau MaduenoGilles EdanAlexandre PratMarc GirardPierre DuquetteMarco OnofrjAlessandra LugaresiPierre GrammondJonathan CironAurélie RuetSerkan OzakbasJérôme de SèzeCéline LouapreHélène ZéphirMaria Jose SaPatrizia SolaDiana FerraroPierre M LabaugeGilles-Louis DeferRoberto BergamaschiChristine Lebrun-FrénayCavit BozElisabetta CartechiniThibault MoreauDavid-Axel LaplaudJeannette Lechner-ScottFrancois Grand'MaisonOliver GerlachMurat TerziFranco GranellaRaed AlroughaniGerardo IulianoVincent van PeschBart van WijmeerschDaniele Litterio A. SpitaleriAysun SoysalEric BergerJulie Prévost-ZuddasEduardo Aguera-MoralesPamela MccombeTamara Castillo-TrivinoPierre ClavelouJean-Pierre PelletierRecai TurkogluBruno StankoffOlivier GoutEric ThouvenotOlivier HeinzlefYoussef SidhomRiadh GouiderTunde CsepanyAlkhedr AbdullatifBertrand BourreOlivier CasezPhilippe CabreAlexis MontcuquetAbir WahabJean-Philippe CamdessanchéAude MauroussetIvania PatryKarolina HankiewiczCorinne PottierNicolas MaubeugeCéline LabeyrieChantal NifleAlasdair ColesCharles MalpasSandra VukusicHelmut ButzkuevenTomas Kalincik
• Organismes : University of Melbourne The Royal Melbourne Hospital Recherche en Pharmaco-épidémiologie et Recours aux Soins Centre d'Investigation Clinique [Rennes] École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Swinburne University of Technology [Melbourne] Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Hospices Civils de Lyon Fondation Eugène Devic EDMUS University of Melbourne University of Cambridge [Cambridge, UK] Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] First Faculty of Medicine Charles University Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] First Faculty of Medicine Charles University Maladies chroniques, santé perçue, et processus d'adaptation Service de neurologie [CHRU Nancy] Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro Università degli studi di Catania = University of Catania Hospital Universitario Virgen Macarena [Séville] Hospital Universitario Virgen Macarena [Séville] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier de l'Université de Montréal Centre Hospitalier de l'Université de Montréal Centre Hospitalier de l'Université de Montréal Università degli studi "G. d'Annunzio" Chieti-Pescara [Chieti-Pescara] IRCCS Azienda Ospedaliero-Universitaria di Bologna Alma Mater Studiorum Università di Bologna = University of Bologna Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale CIC Bordeaux Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] Service de Neurologie [Strasbourg] CIC Strasbourg CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Université de Lille Universidade do Porto = University of Porto Centro Hospitalar do Porto Azienda Ospedaleria Universitaria di Modena = University Hospital of Modena Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Service de Neurologie [CHU Caen] Istituto di Ricovero e Cura a Carattere Scientifico Unité de Recherche Clinique Côte d’Azur Karadeniz Technical University Università degli Studi di Macerata = University of Macerata Macerata Hospital = AST Macerata Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Centre Hospitalier Universitaire de Nantes = Nantes University Hospital University of Newcastle [Callaghan, Australia] John Hunter Hospital Zuyderland Hospital [Heerlen, The Netherlands] Ondokuz Mayis University Università degli studi di Parma = University of Parma Azienda Ospedaliero-Universitaria di Parma = Maggiore Hospital in Parma Amiri hospital Azienda Sanitaria Locale [Salerno] Cliniques Universitaires Saint-Luc [Bruxelles] Université Catholique de Louvain = Catholic University of Louvain Hasselt University San Giuseppe Moscati Hospital [Avellino, Italie] Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Service de Neurologie [CHRU Besançon] Instituto Maimonides de Investigación Biomédica de Cordoba The University of Queensland Royal Brisbane and Women's Hospital [Herston, Queensland, Australia] BioDonostia Health Research Institute = Instituto de Investigación Sanitaria Biodonostia Hospital Universitario Donostia [San Sebastian, Spain] Service Neurologie [CHU Clermont-Ferrand] Neuro-Dol Hôpital de la Timone [CHU - APHM] Aix Marseille Université Haydarpasa Numune Training and Research Hospital Institut du Cerveau = Paris Brain Institute CHU Saint-Antoine [AP-HP] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Centre Hospitalier Universitaire de Nîmes Institut de Génomique Fonctionnelle Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Hopital de Razi - Razi Hospital [Tunis] Hopital de Razi - Razi Hospital [Tunis] University of Debrecen CHU Amiens-Picardie Hôpital Charles Nicolle [Rouen] Centre Hospitalier Universitaire [CHU Grenoble] Hôpital Pierre Zobda-Quitman [CHU de la Martinique] Hôpital Dupuytren [CHU Limoges] CHU Henri Mondor [Créteil] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Hôpital Bretonneau Centre Hospitalier Sud Francilien Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier René Dubos [Pontoise] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Service de neurologie [Le Kremlin Bicêtre] Centre Hospitalier de Versailles André Mignot University of Cambridge [Cambridge, UK] University of Melbourne The Royal Melbourne Hospital Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Université Claude Bernard Lyon 1 Monash University [Melbourne] University of Melbourne The Royal Melbourne Hospital
• Publié dans Multiple Sclerosis Journal le 31/10/2020

---

Résumé : Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups.Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation.Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants.Results: High baseline disability scores, annualised relapse rate (ARR) ⩾ 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) < 6 and ARR < 1 had mean lag of 26.6 weeks (95% CI = 18.2-34.9), males with EDSS < 6 and ARR < 1 31.0 weeks (95% CI = 25.3-36.8), females with EDSS < 6 and ARR ⩾ 1 44.8 weeks (95% CI = 24.5-65.1), and females with EDSS ⩾ 6 and ARR < 1 54.3 weeks (95% CI = 47.2-61.5).Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag

---

Fichiers liés : Roos-2021-DETERMINANTS OF THERAPEUTIC LAG IN MULTIPLE SCLEROSIS.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 11/01/2021
• Auteurs : Ronan ScanffDavid NéronPierre LadevèzePhilippe BarabinotFrédéric CugnonJean-Pierre Delsemme
• Organismes : Siemens Industry Software SAS (Chatillon) Laboratoire de mécanique et technologie Laboratoire de mécanique et technologie Laboratoire de mécanique et technologie Siemens Industry Software SAS (Chatillon) Samtech Samtech

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/01/2021
• Auteurs : Grégoire Le GalMarc CarrierLana CastellucciAdam CukerJohn-Bjarne HansenFrederikus KlokNicole LangloisJerrold LevySaskia MiddeldorpMarc RighiniSam WaltersJohn‐bjarne HansenErik KlokLisa Bauman KreuzigerSam SchulmanLeslie SkeithNeil ZakaiNicoletta RivaJonathan DouxfilsSusan KahnArina ten Cate‐hoekStavros KonstantinidesWaleed GhanimaIrene LangJean‐philippe GalanaudThomas MoumnehEsteban GandaraPaolo PrandoniChar WitmerAlejandro Lazo‐langnerHelia Robert‐ebadiFionnuala Ní ÁinleCynthia WuTzu‐fei WangJeffrey ZwickerMandy LauwCihan AyGabriela Cesarman MausPantep AngchaisuksiriMarie SteinerRaquel BartzJean ConnorsMarc SamamaAlex SpyropoulosDavid FaraoniToshiaki IbaClive KearonSuzanne CanniegeterPierre MorangeSigrid BrækkanVania MorelliFernanda Orsi
• Organismes : University of Ottawa [Ottawa] University of Ottawa [Ottawa] University of Ottawa [Ottawa] University of Pennsylvania [Philadelphia] The Arctic University of Norway [Tromsø, Norway] Leiden University Medical Center [Leiden] University of Ottawa [Ottawa] Geneva University Hospitals and Geneva University
• Publié dans Journal of Thrombosis and Haemostasis le 27/10/2020

---

Résumé : Clinical research in venous thromboembolism (VTE) is hindered by variability in the collection and reporting of data and outcomes. A consistent data language facilitates efficiencies, leads to higher quality data, and permits between-study comparisons and evidence synthesis. The International Society on Thrombosis and Haemostasis (ISTH) launched an international task force of more than 50 researchers to develop common data elements for clinical research in venous thromboembolism. The project was organized in seven working groups, each focusing on a topic area: General Core Data Elements; Anticoagulation and Other Therapies; Chronic VTE and Functional Outcomes; Diagnosis of VTE; Malignancy; Perioperative; and Predictors of VTE. The groups met via teleconference to collaboratively identify key data elements and develop definitions and data standards that were structured in a project-specific taxonomy. A Steering Committee met by teleconference and in-person to determine the overall scope of the project and resolve questions arising from the working groups. ISTH held an open public comment period to enable broader stakeholder involvement and feedback. The common data elements were then refined by the working groups to create a set of 512 unique data elements that are publicly available at http://isth.breakthrough.healthcare. The ISTH VTE Common Data Elements are intended to be a living project with ongoing curation, future expansion, and adaptation to meet the needs of the thrombosis and hemostasis research community.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/01/2021
• Auteurs : Roderau OuthCaroline BoutinPhilippe GueudetMarcelino SuzukiMatthieu SaadaHugues Aumaître
• Organismes : Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Saint Jean de Perpignan Laboratoire de Biodiversité et Biotechnologies Microbiennes Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Saint Jean de Perpignan
• Publié dans Journal of Microbiology, Immunology and Infection le 26/10/2020

---

Résumé : Objectives: To analyse the diagnostic performance of eosinopenia, alone or combined with polymorphonuclear neutrophils (PMN) and/or lymphocytes, as a marker of active COVID-19 in patients hospitalized for suspicion of SARS-CoV-2 infection. Methods: A prospective observational study including patients hospitalized for suspicion of COVID-19 in a COVID unit was performed from 20th March to 5th April 2020, in Perpignan, France. Patients for which there was a doubt upon diagnosis, who were recently under oral corticosteroids, had myeloid malignancy or human immunodeficient virus infection were excluded. SARS-CoV-2 detection was performed using an RT-PCR assay, from nasopharyngeal swab specimens. Complete blood count were performed for all patients. Results: One-hundred and twenty-one patient were included: 57 patients were diagnosed with COVID-19, 64 patients were not. Eosinophil count was lower in the COVID-19 group (median: 0/μL versus 70/μL, p < 0.0001). To diagnose COVID-19, eosinopenia had a sensitivity of 89.5% and a specificity of 78.1% while lymphopenia's were 73.7% and 62.5% respectively. Using area under curve (AUC) of receiving operating characteristics (ROC) curves, eosinophil's optimal cut-off level was 10/μL, sensitivity and specificity were 86%, and 79.7% respectively. Regarding the eosinophil/PMN ratio, the optimal cut-off level was 3.344, sensitivity and specificity were 87.7% and 73.4% respectively. The AUC of lymphocyte/PMN ratio was significantly lower than eosinophil/PMN ratio's (0.621 versus 0.846, p = 0.0003). Conclusion: Eosinopenia - <10/μL - and eosinophil/PMN ratio are useful, low-cost, reproducible tools to help diagnose COVID-19, during an epidemic period, in a population of hospitalized patients admitted for suspicion of COVID-19.

---

Fichiers liés : 1-s2.0-S1684118221000037-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/01/2021
• Auteurs : Aurore GardeLaurent GuibaudAlice GoldenbergFlorence PetitRodolphe DardJoelle RoumeJuliette Mazereeuw-HautierNicolas ChassaingDidier LacombeFanny Morice-PicardA ToutainStéphanie ArpinOlivia BoccaraRenaud TourainePatricia BlanchetChristine CoubesMarjolaine WillemsLucile PinsonPhilippe KHAU VAN KIENChristine ChiaveriniFabienne GiulianoJean-Luc AlessandriMichèle Mathieu-DramardGilles MorinAnne-Claire BursztejnCyril MignotDiane DoummarFrederico Di RoccoJenny CornatonClaire NicolasElodie. GautierMaxime LuuMarc BardouArthur SorlinChristophe PhilippePatrick EderyMassimiliano RossiVirginie CarmignacChristel Thauvin-RobinetPierre VabresLaurence Faivre
• Organismes : Service Dermatologie [CHU Toulouse] Service Génétique Médicale [CHU Toulouse] Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux)
• Publié dans Clinical Genetics le 30/10/2020

---

Résumé : Megalencephaly-CApillary malformation-Polymicrogyria (MCAP) syndrome results from somatic mosaic gain-of-function variants in PIK3CA. Main features are macrocephaly, somatic overgrowth, cutaneous vascular malformations, connective tissue dysplasia, neurodevelopmental delay, and brain anomalies. The objectives of this study were to describe the clinical and radiological features of MCAP, to suggest relevant clinical endpoints applicable in future trials of targeted drug therapy. Based on a French collaboration, we collected clinical features of 33 patients (21 females, 12 males, median age of 9.9 years) with MCAP carrying mosaic PIK3CA pathogenic variants. MRI images were reviewed for 21 patients. The main clinical features reported were macrocephaly at birth (20/31), postnatal macrocephaly (31/32), body/facial asymmetry (21/33), cutaneous capillary malformations (naevus flammeus 28/33, cutis marmorata 17/33). Intellectual disability was present in 15 patients. Among the MRI images reviewed, the neuroimaging findings were megalencephaly (20/21), thickening of corpus callosum (16/21), Chiari malformation (12/21), ventriculomegaly/hydrocephaly (10/21), cerebral asymmetry (6/21) and polymicrogyria (2/21). This study confirms the main known clinical features that defines MCAP syndrome. Taking into account the phenotypic heterogeneity in MCAP patients, in the context of emerging clinical trials, we suggest that patients should be evaluated based on the main neurocognitive expression on each patient.

---

Source

---

• Type de publi. : Rapport
• Date de publi. : 05/01/2021
• Auteurs : Émilie DubreucqMatthieu ThivetChristelle SanchezDavid BardelPhilippe BarralMarion BerrangerVeronica CicolaniFrédéric CruzJean-Loup FlouestLuc JaccotteyRégis LabeauneNicolas MonotValérie TaillandierGrégory VideauPierre Colin de Verdière
• Organismes : Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés Laboratoire Chrono-environnement (UMR 6249) Laboratoire Chrono-environnement (UMR 6249) Institut national de recherches archéologiques préventives Laboratoire Chrono-environnement (UMR 6249) Institut de Recherches sur les Archéomatériaux Archéologie et Philologie d'Orient et d'Occident Ghent Archaeological Team Archéologie, Terre, Histoire, Sociétés [Dijon] Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives Laboratoire Chrono-environnement (UMR 6249) Institut national de recherches archéologiques préventives

---

Résumé : Le PCR : La confluence Saône-Doubs à l’âge du Fer (VIe s. av. J.-C. au Ier siècle de notre ère), coordonné par Matthieu Thivet et Émilie Dubreucq, vise à relancer une dynamique de recherche sur un secteur géographique clé : la confluence de la Saône et du Doubs, située en plein coeur de la Bourgogne, à une vingtaine de kilomètres au nord de Chalon-sur-Saône. Nous souhaitons travailler d’une part, sur les interactions hommes/environnement dans la longue durée (VIe-Ier siècle), afin de mieux percevoir le rôle joué par la zone de confluence dans l’émergence d’un important pôle de peuplement à l’âge du fer. D’autre part nous aborderons la question de la proto-urbanisation et des modalités de développement des agglomérations ouvertes à spécialisation artisanale et commerciale au cours de l'âge du Fer, dont le Verdunois peut s'enorgueillir de posséder deux cas emblématiques : Bragny-sur-Saône « Sous Moussière » et Verdun-sur-le-Doubs « Petit chauvort ». Pour répondre aux multiples problématiques soulevées, la force du programme repose sur son interdisciplinarité, en compilant des approches à la fois documentaires, archéologiques, géophysiques et spatiales.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/01/2021
• Auteurs : Francis CouturaudLaurent BertolettiJean PastrePierre-Marie RoyRaphael Le MaoFrédéric GagnadouxNicolas PaleironJeannot SchmidtOlivier SanchezElodie de MagalhaesMariam KamaraClément HoffmannLuc BressolletteMichel NonentCécile TromeurPierre-Yves SalaunSophie BarillotFlorence GatineauPatrick MismettiPhilippe GirardKarine LacutCatherine LemariéGuy MeyerChristophe Leroyer
• Organismes : Département de Médecine Interne et Pneumologie [Brest] Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne
• Publié dans JAMA Cardiology le 25/10/2020

---

Résumé : Background Information is lacking as to the management of patients with superficial venous thrombosis (SVT) whose profile has been excluded from trials, such as patients with active cancer, severe renal impairment, or pregnancy. Objectives To describe the frequency and management of SVT occurring in these situations. Methods We retrospectively analyzed the frequency, management and evolution of all patients with isolated SVT associated with either active cancer, severe renal impairment, or pregnant or postpartum women, diagnosed in 2 university hospital between January 1st, 2015 and December 31st, 2016. Results Of the 594 isolated SVTs individualized from the 7941 reports screened, 149 SVTs (105 in the upper extremity, 44 in the lower extremity) were analyzed: 94 (63%) associated with active cancer, 27 (18%) with severe renal impairment and 30 (20%) pregnant or postpartum women. SVT was treated with anticoagulant in 34 (36%) patients with cancer, 3 (11%) patients with severe renal impairment and 19 (63%) pregnant or postpartum women. At 3-month, 16 patients (10.8%) had a further venous thromboembolic event, 8 (5.4%) major bleeding, and 9 (6.1%) died. Conclusion SVT in patients with active cancer, severe renal impairment and pregnant or postpartum women represents a quarter of isolated SVTs diagnosed. Heterogeneity of treatment patterns mainly affects patients with cancer and severe renal impairment. Poor outcomes, although probably linked to morbidity, call for dedicated research in these specific situations.

---

Source